PAVM News
Cancer-Screening Test Developer Jumps 28% as Medicare Payments Begin
Confirmation that Medicare is now paying for a cancer-screening test sent its developer sharply higher on Friday. Lucid Diagnostics Inc. (NASDAQ: LUCD), a New York cancer-prevention diagnostics company and subsidiary of medical technology company PAVmed Inc. (NASDAQ: PAVM), said it has begun receiving Medicare payments for its EsoGuard Esophageal DNA Test. The company also closed a $15.0M private placement of Series C convertible preferred stock with existing long-term shareholders on October 21.Recall, Lucid said on September 22 that it would begin submitting Medicare claims for ...
AllPennyStocks.com
Cancer-Screening Test Developer Jumps 28% as Medicare Payments Begin
Confirmation that Medicare is now paying for a cancer-screening test sent its developer sharply higher on Friday. Lucid Diagnostics Inc. (NASDAQ: LUCD), a New York cancer-prevention diagnostics company and subsidiary of medical technology company PAVmed Inc. (NASDAQ: PAVM), said it has begun receiving Medicare payments for its EsoGuard Esophageal DNA Test. The company also closed a $15.0M private placement of Series C convertible preferred stock with existing long-term shareholders on October 21.Recall, Lucid said on September 22 that it would begin submitting Medicare claims for ...
AllPennyStocks.com
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard and Closes $15 Million Financing
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard and Closes $15 Million Financing Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard and Closes $15 Million FinancingPR NewswireNEW YORK, Oct. 22, 2026 Lucid is now submitting Medicare claims and receiving...
PR Newswire
Lucid Diagnostics Advances Multiple EsoGuard and EsoCheck Payment, Billing and Coding Pathways
Lucid Diagnostics Advances Multiple EsoGuard and EsoCheck Payment, Billing and Coding Pathways Lucid Diagnostics Advances Multiple EsoGuard and EsoCheck Payment, Billing and Coding PathwaysPR NewswireNEW YORK, Sept. 22, 2026 Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill...
PR Newswire
Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom...
Benzinga
PAVmed (PAVM) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results PR Newswire NEW YORK, Aug. 14, 2026 Veris Health accelerated its commercial engagement with OSU-The JamesVeris Health implantable...
PR Newswire
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results PR Newswire NEW YORK, Aug. 13, 2026 Recognized 2Q26 revenue of $1.5 millionProcessed 2,770 EsoGuard testsSecured...
PR Newswire
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard Esophageal DNA Test
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard Esophageal DNA Test Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard Esophageal DNA Test PR Newswire NEW YORK, Aug. 5, 2026 Concert's policy...
PR Newswire
Lucid Diagnostics to Participate in Upcoming Investor Conferences
Lucid Diagnostics to Participate in Upcoming Investor Conferences Lucid Diagnostics to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, Aug. 4, 2026 NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.(Nasdaq: LUCD)("Lucid" or the "Company"), a commercial-stage, cancer...
PR Newswire
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026 PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026 PR Newswire NEW YORK, July 31, 2026 Conference Call and Webcast at 8:30 AM ETNEW YORK, July 31, 2026...
PR Newswire